Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes
Diabetes Care · 2023
DOI: 10.2337/dc22-2395 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2023. Verfasst von Christof M Kazda und 8 weiteren Autor:innen. Beteiligte Einrichtung: 1Lilly France, Neuilly sur Seine, France. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypoglycemia. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Basal Insulin Fc (BIF; insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed safety and efficacy of BIF versus degludec in 265 patients with type 1 diabetes (T1D) using multiple daily injections. RESEARCH DESIGN AND METHODS During this randomized, parallel, open-label study, patients with T1D were randomized (1:1) to receive BIF once weekly or degludec once daily over the 26-week treatment period. Both groups were titrated to a fasting glucose level of 80–100 mg/dL. The primary end point was HbA1c change from baseline to week 26 (noninferiority margin, 0.4%). Secondary end points included percent time in range (TIR) (70–180 mg/dL), continuous glucose monitoring (CGM) fasting glucose (FG) level, and rate of hypoglycemia. RESULTS After 26 weeks, patients receiving BIF had noninferior HbA1c change from baseline versus those receiving degludec, with a statistically significant treatment difference of 0.17% (90% CI 0.01, 0.32; P = 0.07) favoring the comparator. Percent TIR was similar for patients in the BIF (56.1%) and degludec (58.9%; P = 0.112) groups at week 26. FG values were significantly higher for patients receiving BIF (158.8 mg/dL) versus degludec (143.2 mg/dL; P = 0.003). Rates of CGM-derived hypoglycemia were not statistically significantly different for BIF and degludec over 24 h for level 1 (P = 0.960) or level 2 (P = 0.517) hypoglycemia during the treatment period. Occurrence of serious adverse events was similar between the BIF and degludec groups. CONCLUSIONS Once-weekly BIF demonstrated noninferior glycemic control to once-daily degludec (treatment difference: 0.17% favoring degludec) and no difference in hypoglycemia or other safety findings in patients with T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Lilly France, Neuilly sur Seine, France.
- 2Eli Lilly and Company, Indianapolis, IN.
- 3Gemeinschaftspraxis für Innere Medizin und Diabetologie, Hamburg, Germany.
ORCID-Profile: Juliana M Bue-Valleskey
Förderung
- Eli Lilly and Company
Zitieren
APA
Kazda, C. M., Bue-Valleskey, J. M., Chien, J., Zhang, Q., Chigutsa, E., Landschulz, W., Wullenweber, P., Haupt, A., & Dahl, D. (2023). Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc22-2395
Vancouver
Kazda CM, Bue-Valleskey JM, Chien J, Zhang Q, Chigutsa E, Landschulz W, et al. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes. Diabetes Care. 2023. doi:10.2337/dc22-2395
BibTeX
@article{Kazda2023,
author = {Kazda, Christof M and Bue-Valleskey, Juliana M and Chien, Jenny and Zhang, Qianyi and Chigutsa, Emmanuel and Landschulz, William and Wullenweber, Paula and Haupt, Axel and Dahl, Dominik},
title = {Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes},
journal = {Diabetes Care},
year = {2023},
doi = {10.2337/dc22-2395}
}
EUVIMED